NCT00551850已完成1 期
A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 4
- 主要终点
- Evaluate the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of AV-412 administered orally 3 times weekly and once weekly in subjects with relapsed or refractory solid tumor malignancies.
研究概览
简要总结
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors. AV-412 is a novel inhibitor of the EGFR-tyrosine kinase, with added activity against Her2 and other oncogenic kinases. Based on evidence of preclinical activity in various solid tumors, AV-412 is being developed as a possible novel treatment for cancer in humans.
PURPOSE: The purpose of this study is to test the safety and tolerability of AV-412, and determine the maximum tolerated dose of AV-412 when administered orally three times weekly.
详细描述
This is an open-label, dose escalation trial, and all subjects will receive oral AV-412 administered three times weekly or once weekly for 4 weeks (1 cycle) to evaluate safety and tolerability of AV-412. Treatment duration will be a minimum of 2 consecutive dosing cycles (8 weeks), if tolerated.
- Upon completion of the 2 cycles, subjects with documented stable disease or an objective response may continue to receive therapy at the same dose and schedule previously utilized, as long as tolerability is acceptable, for up to 1 year. Treatment beyond 1 year from the time of enrollment will be reviewed on a case-by-case basis between the sponsor and investigator.
- Subjects experiencing unacceptable toxicities or with documented disease progression will be discontinued from further participation in the study Accrual to next cohort will occur only after acceptable tolerance has been demonstrated throughout Cycle 1, and only after consultation with medical monitor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to give written informed consent
- •18 years and older
- •Evaluable disease or measurable disease according to RECIST.
- •Subjects enrolled in the MTD Cohort B must have the following:
- •A diagnosis of non-small cell lung carcinoma (NSCLC)
- •Received prior therapy with erlotinib or gefitinib for a minimum of 12 weeks
- •Demonstrated disease stabilization or an objective response during that prior treatment
- •Evidence of disease progression and measurable disease, according to RECIST
- •Histologically confirmed solid tumor malignancy that is locally advanced or metastatic
- •Disease that is currently refractory to, or not amenable to, standard therapy and/or subjects who are unwilling to try standard chemotherapy
- •Disease that is currently not amenable to surgical intervention, due to either medical contraindications or non-resectability of the tumor
- •Karnofsky performance status ≥ 70%
- •Life expectancy ≥ 3 months, as judged by the investigator
- •No childbearing potential; or use of a medically acceptable form of contraception during the study through the end of follow-up period
排除标准
- •Pregnant or lactating women
- •Primary CNS malignancy and/or active CNS metastases (or leptomeningeal disease) not controlled by prior surgery or radiotherapy
- •Hematologic malignancies (including leukemia of any form, lymphoma, and multiple myeloma)
- •Active second malignancy or history of another malignancy within 2 years with the exception of:
- •Treated, non-melanoma skin cancers
- •Treated carcinoma in situ (CIS) of the breast or cervix
- •Controlled, superficial carcinoma of the bladder
- •T1a or b prostate carcinoma comprising < 5% of resected tissue, with prostate specific antigen (PSA) within normal limits (WNL) since resection
- •Any of the following hematologic abnormalities:
- •Hemoglobin ≤ 9.0 g/dL
- •ANC ≤ 1500 per mm3
- •Platelet count ≤ 75,000 per mm3
- •Any of the following serum chemistry abnormalities:
- •Total bilirubin > 1.5 × the ULN
- •AST or ALT ≥ 3 × ULN (≥ 5 × ULN if due to hepatic involvement by tumor)
- •Serum albumin < 2.5 g/dL
- •Creatinine ≥ 1.5 × ULN
- •Significant cardiovascular disease or condition, including:
- •Congestive heart failure requiring therapy
- •Ventricular arrhythmia requiring therapy
- •Severe conduction disturbance (including QTc interval prolongation > 0.47 sec [corrected], history of a severe arrhythmia, or history of a familial arrhythmia [eg, Wolff-Parkinson-White syndrome])
- •Angina pectoris requiring therapy
- •Left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram
- •Uncontrolled hypertension (as determined by investigator)
- •Myocardial infarction (MI) within 6 months prior to administration of first dose
- •>Class I cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria
- •Significant gastrointestinal abnormalities, including:
- •Requirement for IV alimentation
- •Prior surgical procedures affecting absorption
- •Active peptic ulcer disease
- •Grade 2 diarrhea due to any etiology
- •Ulcerative colitis or Crohn's disease
- •Known history of significant ophthalmologic abnormalities, including:
- •Severe dry eye syndrome
- •Keratoconjunctivitis sicca
- •Sjogren's syndrome
- •Severe exposure keratopathy
- •Disorders that might increase the risk for epithelium-related complications (eg, bullous keratopathy, aniridia, severe chemical burns, neutrophilic keratitis)
- •Serious/active infection or any infection requiring parenteral antibiotics
- •Inadequate recovery from prior antineoplastic therapy
- •Inadequate recovery from any prior surgical procedure or major surgical procedure within 2 weeks prior to administration of first dose
- •Life-threatening illness, or organ system dysfunction which, in the opinion of the investigator, would limit life expectancy to < 3 months, compromise the subject's safety, or interfere with evaluation of the safety of the study drug
- •Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study procedures
- •Inability to comply with the protocol requirements
- •Drugs and Treatments to be Excluded:
- •Any prior therapy with the following:
- •Doxorubicin at a cumulative dose > 450 mg/m2 or equivalent dose of another anthracycline (eg, daunorubicin, epirubicin, idarubicin) or anthracenedione (eg, mitoxantrone).
- •HKI-272 or any other irreversible EGFR tyrosine kinase inhibitor (eg, CI- 1033 and similar agents).
- •Therapy within 2 weeks prior to administration of the first dose or at any time during the study with:
- •Herbal preparations/supplements (except for a daily multivitamin/mineral supplement not containing herbal components)
- 另有 20 项未显示
研究组 & 干预措施
1
Experimental
干预措施: AV-412 (Drug)
结局指标
主要结局
Evaluate the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of AV-412 administered orally 3 times weekly and once weekly in subjects with relapsed or refractory solid tumor malignancies.
时间窗: 4 weeks (1 cycle)
次要结局
- Characterize the pharmacokinetic (PK) profile of AV-412(8 weeks ( 2 cycles))
- Determine the effect of AV-412 on global and targeted gene expression patterns in blood from all subjects enrolled in the MTD expansion cohorts(8 weeks (2 cycles))
- Evaluate the antineoplastic activity of AV-412(8 weeks (2 cycles))
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLCNon-small Cell Lung CancerNCT01528488Sun Yat-sen University118
进行中（未招募）
不适用
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin RashAcneiform EruptionsNCT05120362Shanghai East Hospital12
已完成
不适用
Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor InhibitorsEpidermal Growth Factor Receptor InhibitorParonychiaNCT06411093Chang Gung Memorial Hospital24
已完成
1 期
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerNon Small Cell Lung CancerNCT01121575Pfizer70
已完成
2 期
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side EffectsColorectal CancerPancreatic CancerNon-small Cell Lung CancerNCT02284139Dong-A University Hospital90